+

PE20090880A1 - Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa - Google Patents

Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa

Info

Publication number
PE20090880A1
PE20090880A1 PE2008001259A PE2008001259A PE20090880A1 PE 20090880 A1 PE20090880 A1 PE 20090880A1 PE 2008001259 A PE2008001259 A PE 2008001259A PE 2008001259 A PE2008001259 A PE 2008001259A PE 20090880 A1 PE20090880 A1 PE 20090880A1
Authority
PE
Peru
Prior art keywords
amino
phosphatidylinositol
bencensulfonamide
pyrimidin
methyl
Prior art date
Application number
PE2008001259A
Other languages
English (en)
Inventor
Ian Bruce
Andrew Dunstan
Thomas Anthony Hunt
Catherine Howsham
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20090880A1 publication Critical patent/PE20090880A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO HETEROCICLICO DE FORMULA (I), DONDE R1 ES H; R2 ES H O AMINO; A ES CR3; B ES CR3a O N; Ar' ES UN GRUPO (a), UN ARILO DE 6 A 14 CARBONOS, UN GRUPO HETEROARILO DE 5 A 10 MIEMBROS, ENTRE OTROS; E ES CH O N; R3 Y R3a SON H, ALQUILO C1-C6, HALOALQUILO C1-C6, ENTRE OTROS; R5 ES OH, ALQUILO C1-C6, HALOALQUILO C1-C6, ENTRE OTROS; R6 ES H, HALO, OH, CIANO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 5-(2-AMINO-4-METIL-PIRIMIDIN-5-IL)-2-CLORO-N-(3-CIANO-FENIL)-BENCENSULFONAMIDA, 5-(2-AMINO-4-METIL-PIRIMIDIN-5-IL)-2-BROMO-N-FENIL-(2-HIDROXI-ETIL)-BENCENSULFONAMIDA, 5-(2-AMINO-2-METIL-PIRIMIDIN-5-IL)-2-BROMO-N-PROPIL-BENCENSULFONAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS INHIBEN LA ENZIMA DE FOSFATIDILINOSITOL 3-CINASA (P1 3-CINASA), PARTICULARMENTE, GAMMA-ISOFORMA (p110 GAMMA), Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS DE LAS VIAS RESPIRATORIAS, DE LA PIEL, ENTRE OTRAS
PE2008001259A 2007-07-26 2008-07-24 Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa PE20090880A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07113237 2007-07-26

Publications (1)

Publication Number Publication Date
PE20090880A1 true PE20090880A1 (es) 2009-08-06

Family

ID=38942282

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001259A PE20090880A1 (es) 2007-07-26 2008-07-24 Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa

Country Status (21)

Country Link
EP (1) EP2173722B1 (es)
JP (1) JP5485884B2 (es)
KR (1) KR20100025006A (es)
CN (1) CN101765591B (es)
AR (1) AR067869A1 (es)
AU (1) AU2008278966B2 (es)
BR (1) BRPI0813629A2 (es)
CA (1) CA2694275A1 (es)
CL (1) CL2008002185A1 (es)
CO (1) CO6290670A2 (es)
CR (1) CR11208A (es)
EA (1) EA201000104A1 (es)
EC (1) ECSP109900A (es)
ES (1) ES2394126T3 (es)
MA (1) MA31594B1 (es)
MX (1) MX2010001020A (es)
PE (1) PE20090880A1 (es)
SV (1) SV2010003464A (es)
TN (1) TN2010000038A1 (es)
TW (1) TW200909426A (es)
WO (1) WO2009013348A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268834B2 (en) * 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
GB0815947D0 (en) * 2008-09-02 2008-10-08 Univ Dundee Compounds
JP2012521354A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
JP4967004B2 (ja) * 2009-09-14 2012-07-04 東京エレクトロン株式会社 レジスト塗布現像装置およびレジスト塗布現像方法
ES2908042T3 (es) 2014-01-14 2022-04-27 Takeda Pharmaceuticals Co Heteroarilos y usos de los mismos
WO2015108881A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EA032075B1 (ru) 2014-04-24 2019-04-30 Новартис Аг Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы
CN106458980A (zh) 2014-04-24 2017-02-22 诺华股份有限公司 作为磷脂酰肌醇3‑激酶抑制剂的氨基吡啶衍生物
KR20160141856A (ko) 2014-04-24 2016-12-09 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
BR112020012651A2 (pt) 2017-12-22 2020-12-01 Ravenna Pharmaceuticals, Inc. compostos derivados de aril-bipiridina amina como inibidores da fosfatidilinositol fosfato quinase, composição farmacêutica compreendendo os mesmos e usos terapêuticos dos ditos compostos
ES2910071T3 (es) 2018-03-08 2022-05-11 Incyte Corp Compuestos de aminopirazina diol como inhibidores de PI3K-Y
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW520362B (en) * 1996-12-05 2003-02-11 Amgen Inc Substituted pyrimidine compounds and pharmaceutical composition comprising same
CN1438890A (zh) * 2000-02-25 2003-08-27 弗·哈夫曼-拉罗切有限公司 腺苷受体调制剂
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
AU2002310187A1 (en) * 2001-05-30 2002-12-09 Lg Biomedical Institute Inhibitors of protein kinase for the treatment of disease
AUPR688101A0 (en) * 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI330183B (es) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
AU2002950853A0 (en) * 2002-08-19 2002-09-12 Fujisawa Pharmaceutical Co., Ltd. Aminopyrimidine compound and pharmaceutical use thereof
US7405221B2 (en) * 2002-09-27 2008-07-29 Merck & Co., Inc. Substituted pyrimidines
MXPA05005477A (es) * 2002-11-21 2005-07-25 Chiron Corp Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer.
CN1735607B (zh) * 2002-11-21 2010-06-09 诺华疫苗和诊断公司 2,4,6-三取代的嘧啶作为磷脂酰肌醇(pi)3-激酶抑制剂及其在治疗癌症中的应用
MEP52808A (en) * 2003-02-26 2011-05-10 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
JP2007521293A (ja) * 2003-06-30 2007-08-02 メルク　エンド　カムパニー　インコーポレーテッド アンドロゲン受容体モジュレータとしての１７−アセトアミド−４−アザステロイド誘導体
ES2229928B1 (es) * 2003-10-02 2006-07-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirimidin-2-amina.
WO2006015123A1 (en) * 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
SE0402735D0 (sv) * 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
UY29414A1 (es) * 2005-03-10 2006-10-02 Bayer Pharmaceuticals Corp Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
AU2007231577B2 (en) * 2006-03-22 2012-07-19 Vertex Pharmaceuticals Incorporated c-MET protein kinase inhibitors for the treatment of proliferative disorders
GB0608820D0 (en) * 2006-05-04 2006-06-14 Piramed Ltd Pharmaceutical compounds
GB0610242D0 (en) * 2006-05-23 2006-07-05 Novartis Ag Organic compounds
ES2379830T3 (es) * 2006-07-28 2012-05-04 Novartis Ag Quinazolinas sustituidas en 2,4- como inhibidores de quinasa lipídica
EP2057158B8 (en) * 2006-08-30 2015-09-30 Cellzome Limited Triazole derivatives as kinase inhibitors
AR067354A1 (es) * 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc Compuestos utiles como inhibidores de la raf quinasa

Also Published As

Publication number Publication date
CO6290670A2 (es) 2011-06-20
TN2010000038A1 (en) 2011-09-26
TW200909426A (en) 2009-03-01
JP2010534634A (ja) 2010-11-11
ECSP109900A (es) 2010-02-26
SV2010003464A (es) 2010-05-21
CL2008002185A1 (es) 2009-02-20
AU2008278966B2 (en) 2012-02-23
EP2173722A2 (en) 2010-04-14
MA31594B1 (fr) 2010-08-02
JP5485884B2 (ja) 2014-05-07
CN101765591B (zh) 2013-11-27
AR067869A1 (es) 2009-10-28
CR11208A (es) 2010-02-12
AU2008278966A1 (en) 2009-01-29
CA2694275A1 (en) 2009-01-29
WO2009013348A2 (en) 2009-01-29
KR20100025006A (ko) 2010-03-08
BRPI0813629A2 (pt) 2018-07-10
CN101765591A (zh) 2010-06-30
MX2010001020A (es) 2010-03-01
EP2173722B1 (en) 2012-08-29
WO2009013348A3 (en) 2009-07-23
EA201000104A1 (ru) 2010-08-30
ES2394126T3 (es) 2013-01-22

Similar Documents

Publication Publication Date Title
PE20090880A1 (es) Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa
MY173930A (en) Crystalline solvates and complexes of (is)-1,5-anhydro-1-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
NI201000107A (es) Derivados de tiazol utilizados como inhibidores de pi 3 - cinasa.
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
MX2011012627A (es) Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
PE20121506A1 (es) Compuestos triazolopiridinas como inhibidores de c-met
PE20080527A1 (es) Derivado de pirimidina como inhibidor de la fosfatidilinositol 3-quinasa (pi3k)
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR082968A1 (es) Inhibidores biciclicos de notum pectinacetilesterasa y una composicion farmaceutica en base al compuesto
TW200716531A (en) Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia
ECSP066383A (es) Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
PE20070833A1 (es) Compuestos de pirimidinil benzotiofeno
SMAP201100019A (it) Composti organici.
PE20081354A1 (es) Compuestos de azaindolilo como inhibidores de mek
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
CO6270285A2 (es) Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida
EA201101621A1 (ru) Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
MX2008016358A (es) Derivados de tiazolil-urea como inhibidores de cinasa de fosfatidil-inositol-3.
ATE492534T1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
DE602006014022D1 (de) 5-substituierte indol-2-carbonsäureamidderivate
PE20080207A1 (es) DERIVADOS DE 1-N-AMINO-2-IMIDAZOLIDINONAS COMO INHIBIDORES DEL CANAL DE POTASIO Kv1.5

Legal Events

Date Code Title Description
FC Refusal
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载